Robert B Scharpf
Overview
Explore the profile of Robert B Scharpf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
6331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruhm D, Vulpescu N, Foda Z, Phallen J, Scharpf R, Velculescu V
Nat Rev Cancer
. 2025 Mar;
PMID: 40038442
Genomic analyses of cell-free DNA (cfDNA) in plasma are enabling noninvasive blood-based biomarker approaches to cancer detection and disease monitoring. Current approaches for identification of circulating tumour DNA typically use...
2.
Jamouss K, Damanakis A, Cornwell A, Jongepier M, Trujillo M, Pfluger M, et al.
J Pathol
. 2025 Feb;
PMID: 40001347
Pancreatic ductal adenocarcinoma (PDAC) poses a significant challenge due to late-stage diagnoses. To improve patient outcomes, early intervention in precursor lesions such as intraductal papillary mucinous neoplasm (IPMN) is crucial....
3.
van t Erve I, Alipanahi B, Lumbard K, Skidmore Z, Rinaldi L, Millberg L, et al.
Nat Commun
. 2024 Oct;
15(1):8801.
PMID: 39433569
Circulating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using...
4.
Medina J, Annapragada A, Lof P, Short S, Bartolomucci A, Mathios D, et al.
Cancer Discov
. 2024 Sep;
15(1):105-118.
PMID: 39345137
There is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that...
5.
Noe M, Mathios D, Annapragada A, Koul S, Foda Z, Medina J, et al.
Nat Commun
. 2024 Aug;
15(1):6690.
PMID: 39107309
Circulating cell-free DNA (cfDNA) is emerging as an avenue for cancer detection, but the characteristics of cfDNA fragmentation in the blood are poorly understood. We evaluate the effect of DNA...
6.
Lai J, Yang Y, Liu Y, Scharpf R, Karchin R
Bioinform Adv
. 2024 Jul;
4(1):vbae094.
PMID: 38948008
Summary: Neoplastic tumors originate from a single cell, and their evolution can be traced through lineages characterized by mutations, copy number alterations, and structural variants. These lineages are reconstructed and...
7.
Teh S, Bowland K, Halper-Stromberg E, Kotwal A, Bennett A, Skaist A, et al.
NAR Cancer
. 2024 Jun;
6(2):zcae028.
PMID: 38915758
Somatic mutations are desirable targets for selective elimination of cancer, yet most are found within noncoding regions. We have adapted the CRISPR-Cas9 gene editing tool as a novel, cancer-specific killing...
8.
Mazzone P, Bach P, Carey J, Schonewolf C, Bognar K, Ahluwalia M, et al.
Cancer Discov
. 2024 Jun;
14(11):2224-2242.
PMID: 38829053
Lung cancer screening via annual low-dose computed tomography has poor adoption. We conducted a prospective case-control study among 958 individuals eligible for lung cancer screening to develop a blood-based lung...
9.
Braxton A, Kiemen A, Grahn M, Forjaz A, Parksong J, Babu J, et al.
Nature
. 2024 May;
629(8012):679-687.
PMID: 38693266
Pancreatic intraepithelial neoplasias (PanINs) are the most common precursors of pancreatic cancer, but their small size and inaccessibility in humans make them challenging to study. Critically, the number, dimensions and...
10.
Annapragada A, Niknafs N, White J, Bruhm D, Cherry C, Medina J, et al.
Sci Transl Med
. 2024 Mar;
16(738):eadj9283.
PMID: 38478628
Genetic changes in repetitive sequences are a hallmark of cancer and other diseases, but characterizing these has been challenging using standard sequencing approaches. We developed a de novo kmer finding...